CTSO - シトソ―ベンツ （Cytosorbents Corporation） シトソ―ベンツCTSOのチャート
CTSOの企業情報
| symbol | CTSO |
|---|---|
| 会社名 | Cytosorbents Corp （シトソ―ベンツ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product CytoSorb which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. In addition CytoSorb is used in other inflammatory conditions such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others. シトソ―ベンツは、免疫療法に特化した米国の医療会社。多臓器不全を治療するために炎症を調節する血液浄化技術プラットフォ―ムを使用して免疫療法を行う。欧州連合で、体外サイトカインフィルタ｢CytoSorb｣デバイスを販売する｡また血液浄化システム｢HomoDefend｣と血液から有毒な薬を取り除く｢DrugSorb｣を開発する。 CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ. |
| 本社所在地 | 7 Deer Park Drive Suite K Monmouth Junction NJ 08852 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 37347 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 84人 |
| url | www.cytosorbents.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ctso |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.01103 |
| 終値（lastsale） | 11.61 |
| 時価総額（marketcap） | 365244133.23 |
| 時価総額 | 時価総額（百万ドル） 360.83980 |
| 売上高 | 売上高（百万ドル） 19.15110 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 345.45086 |
| 当期純利益 | 当期純利益（百万ドル） -14.00454 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytosorbents Corp revenues increased 60% to $10.7M. Net loss increased from $3.3M to $8.8M. Revenues reflect CytoSorb sales increase of 71% to $9.6M Other sales increase from $14K to $88K. Higher net loss reflects General and administrative -other increase of 49% to $7.8M (expense) Stock-based Compensation in SGA increase from $876K to $2.5M (expense). |
CTSOのテクニカル分析
CTSOのニュース
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development 2020/07/31 11:08:00 PR Newswire
MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office…
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data 2020/07/28 11:08:00 PR Newswire
MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients…
CytoSorbents to Report Q2 2020 Operating and Financial Results 2020/07/28 10:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery…
CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock 2020/07/22 11:22:00 Benzinga Feeds
MONMOUTH JUNCTION, N.J. , July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced the pricing of its previously announced underwritten public offering of 5,263,158 shares of its common stock at a public offering price of $9.50 per share, resulting in gross proceeds of approximately $50.0 million before deducting underwriting discounts and commissions and other offering expenses. CTSO ) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation)" alt="CytoSorbents Corporation (NASDAQ: CTSO ) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb.
CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock 2020/07/20 20:27:00 PR Newswire
MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac…
CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock 2020/07/20 20:27:00 PR Newswire
MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac…
CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding 2020/06/29 11:08:00 PR Newswire
MONMOUTH JUNCTION, N.J., June 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces…
Hedge Funds Have Never Been More Bullish On Cytosorbents Corp (CTSO) 2020/06/25 16:27:50 Yahoo Finance
In this article we will take a look at whether hedge funds think Cytosorbents Corp (NASDAQ:CTSO) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise 2020/06/24 11:30:00 PR Newswire
MONMOUTH JUNCTION, N.J., June 24, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the…
CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials 2020/06/09 11:08:00 PR Newswire
MONMOUTH JUNCTION, N.J., June 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract,…
CytoSorbents Announces Virtual Annual Meeting 2020/05/27 16:00:00 Benzinga Feeds
MONMOUTH JUNCTION, N.J. , May 27, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, will host its Virtual Annual Meeting on Tuesday, June 2, 2020 at 10:00 AM EDT . Stockholders of record will be able to virtually join and submit questions, and those that have not yet voted will be able to vote their shares electronically at the meeting. CTSO ) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation)" alt="CytoSorbents Corporation (NASDAQ: CTSO ) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb.
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter 2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery 2020/05/12 11:08:00 PR Newswire
MONMOUTH JUNCTION, N.J., May 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb® is now approved and immediately available in the European Union for the removal of rivaroxaban…
The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda 2020/05/08 11:59:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 7) • Acceleron Pharma Inc (NASDAQ: XLRN ) • Bio-Rad Laboratories, Inc. (NYSE: BIO ) • BIO-TECHNE Corp (NASDAQ: TECH ) • Catalent Inc (NYSE: CTLT ) • Cytosorbents Corp (NASDAQ: CTSO ) • DexCom, Inc. (NASDAQ: DXCM ) • GENMAB A/S/S ADR (NASDAQ: GMAB ) • Immunomedics, Inc. (NASDAQ: IMMU ) • Immunovant Inc (NASDAQ: IMVT ) • Kala Pharmaceuticals Inc (NASDAQ: KALA ) • Masimo Corporation (NASDAQ: MASI ) • Meridian Bioscience, Inc. (NASDAQ: VIVO ) • Minerva Neurosciences Inc (NASDAQ: NERV ) • Natera Inc (NASDAQ: NTRA ) • ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) • Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) • Quidel Corporation (NASDAQ: QDEL ) • Repligen Corporation (NASDAQ: RGEN ) • Revolution Medicines Inc (NASDAQ: RVMD ) • Scpharmaceuticals Inc (NASDAQ: SCPH ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 7) • Apyx Medical Corp (NASDAQ: APYX ) • Biofrontera AG (NASDAQ: BFRA ) • Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN ) Stocks In Focus Pluristem Gets FDA Nod To Initiate Phase 2 Study Of PLX Cells In COVID-19 Pluristem Therapeutics Inc. (NASDAQ: PSTI ) said the FDA cleared its IND application …
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom to Join S&P 500 2020/05/07 11:41:00 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) (reacted to its first-quarter results and clinical pipeline update) AstraZeneca plc (NYSE: AZN ) ( announced FDA approval for label expansion for its Farxiga) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp (NASDAQ: CTSO ) (reacted to its strong first-quarter results) DexCom, Inc. (NASDAQ: DXCM ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-quarter results) Horizon Therapeutics PLC (NASDAQ: HZNP ) (reacted to first-quarter results) I mara Inc (NASDAQ: IMRA ) Immunomedics, Inc. (NASDAQ: IMMU ) Immunovant Inc (NASDAQ: IMVT ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MacroGenics Inc (NASDAQ: MGNX ) (reacted to its first-quarter results and sell-side reactions to the results) Masimo Corporation (NASDAQ: MASI ) Meridian Bioscience, Inc.